Abbott Laboratories

All Financial Data in US $ (mln)

Worldwide

Overview

Company News

Alkermes plc Reports Financial Results for Fiscal Year 2013 and Provides Financial Expectations
Alkermes (May 23, 2013)

Research and Markets: Global Cardiac Bio Implant Devices Market Forecast, Clinical Trials, M&A
Abbott Laboratories (May 23, 2013)

Abbott to Present at Deutsche Bank 38th Annual Health Care Conference
Abbott Laboratories (May 22, 2013)

RBCC Opens Talks to Acquire Tech Innovators in $142 Billion Drug Delivery Market
Rainbow Coral (May 21, 2013)

Abbott Announces CE Mark for World's Longest Coronary Drug Eluting Stent
Abbott Laboratories (May 21, 2013)

Mylan Launches Generic Tricor® Tablets
Mylan (May 17, 2013)

Biosensors expands its horizons with imaging buy

(May 14, 2013)

RBCC Partner n3D Signs U.S. Distribution Agreement
Rainbow Coral (May 13, 2013)

Abbott Announces CE Mark for Test to Aid Doctors with Diagnosing and Monitoring Diabetes
Abbott Laboratories (May 09, 2013)

Warsaw Mayor Hosts Keynote Speakers OrthoPediatrics Founder and ESPN Chief Medical Correspondent at OrthoTec 2013
OrthoPediatrics (May 09, 2013)

Displaying 10 out of a possible 4228 unique stories.
Results Sorted By date
Display All Stories

EvaluatePharma® - the premier source for pharma and biotech analysis.

Expert integration of financial and product data across historic and forecast timeframes (1986 to 2018) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.

Company Profile

Profile	Abbott Laboratories (ABT) is an Illinois based global pharmaceutical & medical device company. Major divisions include: Pharmaceuticals, Diagnostics, Nutritionals, Vascular Products & Other (includes Diabetes Care & Medical Devices for the eye). 01 JAN 2013: Abbott spun-out "AbbVie" as a new research-based pharmaceutical company.
Listed or Private Company	Listed
Company Classification	Global Majors (Pharma); MedTech
Country	USA
Company Website	Website

Full Company Profile Information

EventAnalyzer - Last Key Event

Closing Price DateClosing Price Date	EventAnalyzer Note	Market Cap (US $m)	Change (%)	Change (+$m)
17/10/2012	17 Oct: Company reports mixed Q3'12 results, with earnings beating forecasts but weaker-than-expected sales due to slower growth of arthritis treatment, Humira.	108,347	-4.3%	-4,849

Top 3 Products (Worldwide Sales 2009/10)

				Annual Sales WW - Sales		Growth per Year (%)
Rank¹	Product	Generic Name	Therapeutic Subcategory	2009	2010	2010
1	Humira	adalimumab	Other anti-rheumatics	5,488²	6,548³	+19%
2	TriCor	fenofibrate	Anti-hyperlipidaemics	1,337⁴	1,582⁵	+18%
3	Kaletra	lopinavir; ritonavir	Anti-virals	1,366	1,255	-8%
Note: Shaded Cells⁶

RX Sales Chart

Abbott Laboratories	Data		Growth
	2009	2010	2010
Revenues By Segment
Pharmaceuticals
Pharmaceuticals Sales (In-depth)
Rx & OTC Pharmaceuticals
Prescription (Rx) Pharmaceuticals	16,447⁷	19,834⁸	+21%

Therapy Area Focus in 2010

Abbott Laboratories
	2010
WW Rx & OTC Sales By Therapy Area
Main Categories
Cardiovascular	3,243
Central Nervous System	1,251
Endocrine	1,195
Gastro-Intestinal	575
Genito-Urinary	971
Musculoskeletal	6,548
Oncology & Immunomodulators	804
Respiratory	37
Systemic Anti-Infectives	3,020
Other Rx & OTC Pharma	2,191

EvaluatePharma® Coverage of Marketed and Pipeline Products

	Product Count
Abbott Laboratories ⁹	565

Welcome

Evaluate provides market intelligence and analysis for the pharma, biotech and medtech industries.

Explore Evaluate

Partnering

EvaluatePharma® now includes Partnering Opportunities - products available for licensing.

Partnering Opportunities in EvaluatePharma® are sourced from the rights holders - all entries are verified by the team of Analysts at EvaluatePharma - and presented in their commercial context.

Register to submit your Partnering Opportunities or to see your own and other Partnering Opportunities in their commercial context with the unique industry-wide analysis in EvaluatePharma®.

Take a full subscription to see all products available for license, including updated contact details for the out-licensing entity.


EP Vantage - last 6 months

Biosensors expands its horizons with imaging buy (May 14, 2013)

Covidien aims for AbbVie mk II with Mallinckrodt spinout (May 08, 2013)

Shock adcom endorsement for MitraClip but US approval still a long shot (March 21, 2013)

Event – Tecfidera odds-on for US nod but first-line use not assured (March 07, 2013)

Event – Abbott hopes mitral repair will be the new TAVI (February 27, 2013)

Displaying 5 out of a possible 25 unique stories.
Results Sorted By date
Display All Stories

2011 Product Sales analysis
2011 Pharmaceutical Sales
2011 Market Share & Global Ranking
Download to Excel
Search 2 yrs of company press releases

Ranked on:
Annual Sales WW
2010

Group Total: Equals the sum of values in report based on report grouping.

Note: Where Top 5,10,100 etc filters have been applied, the aggregate value relates to the total of the original unfiltered group - not the displayed filtered data. Where n/a appears, a value has been hidden but is included in Group Total.

Examples:

e.g. Top 100 drugs reports. These are not grouped but are filtered to show only the top 100 products by sales in a particular year. The Group Total displayed is equal to the sum of all data within Evaluate Pharma - not just the top 100 products i.e. total market size.

e.g. Global Majors - Top 10 products. Report is grouped by Company and filtered to show only the top 10 products by sales in a particular year. Group Totals are displayed for each company and are equal to the sum of all available data for that company - not just the top 10 products.

XXXXXXX XXXXXXX:

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXXXXXXX XXXXXX XXXXXX XXXXX XXXXXX XXX XX.X XXXXXXX XXX XXX XXXX-XXXX XXXX, XXXXXXXXX XXX XXXX-XXXX XXXXXXXX XXXXX XXXXXXXX XXX XXX XXXXXXX. XXXXXXXXXXXXX XXXXXXXXXXXXXX XXXXX XX XXX XXXXXX XXXXXXX XXXXXXXXX XX.X XXXXXXX, XXXXXXXXX X X.X XXXXXXX XXXXXXXXX XXXXXX XXXX XXXXXXXX. XXXXXXXXXXXXXXX, XXXXXX XXX XXXXXX XXX XX.X XXXXXXX, XXXX XXXXXXXX XXXXX XX $XXX XXXXXXX. XXXXXXXXXXXXX XXXX-XXX XXXXXX XXXXXX XXXXXX XXXXXX XXXXXX, XXX XXXXXX XXXXXXXXX X XXXXXX-XXXXXXX XXXXXXXX XX XXXX XX XXX XXXXXXXXXXXXX XXXXXXX, XXXXXXXXX XXX XXXXXX XXX XXXXX XXXXXXXX XX XXXXXXX XXXXXX.

XXXXXX: XXXXXX XXXX XX-X, XXXX XX:
XX XXXX, XXXXXX XXXXX XXX XXXXXXXXX XXXXXX XX XXXXXX XXX XXXXXXXXXX XXXXXXXXX, XXXXXXXX XX XXXXXXXX XXX XXXX XXXXXXXXXX XXXXXXXXXXX, XXXXX XXXXXXXXX XXXXXX'X XXXXXXXXX XXXXX XX $X.X XXXXXXX XX XXXX XXXXXXXX XX $X.X XXXXXXX XX XXXX, XXX $X.X XXXXXXX XX XXXX. XXXXXX XXXXXXXXX XXXXXXXXX XXXXXX XXXXX XX XXXXXXXX XX XXXXXXXXXXXXX XX XXXXXXX XX XXXX. XXXXXX XX XXXXXXXX XXXXXXXXXX XXXXXXXXXXX XXX XXXXXX . XXXXXXXXXXX XXXXXXXX XXX XXXXXXXXXXX XXX XXXXXXX XXXXXXX XXX XXXX XXX XXXXXXXXX XX XX XXXXXXXXX XX XXXXXXXXXX XXX XXXXXXXXX XXXXXXXXX XX XXXXXX .

XXXX XX:
XXXXXXXXXXXXX XXXXX XX XXXXXX XXXX $X.X XXXXXXX, $X.X XXXXXXX XXX $X.X XXXXXXX XX XXXX, XXXX XXX XXXX, XXXXXXXXXXXX.

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
XXX XXX XXXX-XXXX XXXX, XXXXXX XX XXXXXXXXXXX XXXXXX XXXXXX XXXXXXXXXXX XXXXX XXXXXX XX XX XX XX XXXXXXX, XXXXXXXXX XXX XXXXXXXX XXXXXX XX XXXXXXXX, XXX XXXXXX XXXXXX XXXXXXXX XXXXX XXXXXX XX XX XX XX XXXXXXX, XXXXXXXXX XXXXXXXX. XXXX XXXXXXXX XXXXXXXXXX XXXXXXXXXXXXX XXXXXXXX XXXXX XXXXXX XX XXXX XXXX XX XXXXXXX, XXXXXXXXX XX XXXXXXXX XXXXXXXX XXXXXX XXXX XXXXXXXX XXXXXXXXXXX XX XXXXXXX, XXX X.X. XXXXXX XXXXXX XX XXX XXX XXXXXX-XXXXXX. XXX XXXXXXX XXXX-XXXX XXXXXX XXXXXXXX XXXXXXXX XXXXXXX XXXXXX XXXXXXXX XX XXXX XX XXXXXXXX XXXXXXXX XXXX XXXXXX.

XXXXXX: XXXXXX XXXX XXXXXX XXXXXX, XXXX XX:
XXXX XXX XXXXXXXX XXXXXXXXXX XXXXXXXXXXX, XXXXXX XX X XXXXXXX XXXXXXXX XXXXXXX. XXX XXXXXXXXXX XXXXXXXXXX XXXXXXXXXX XXXX XXXXX XXXXX XXXXX XXXXXXXXXXX XXXXXXXXXX XXXXXXXX XXXXXX XX X XXXXXX XXXXXXXXXX XXX XXX XXXXXXXX XX XXXXXXXXXX. XX XXXXXXXX XX XXXXXXXXXX XXXXXX XXX XXXXXXXXXX XXXXXXXXX XXXXXXXXXXX, XX’XX XXXXXXXXXXX X XXXXXX XX XXXXXXXXX XXXXXXXXXXX XXXXXXXXX — XXXX XXXXXXXX XXX XXXXX-XXXXXXXX — XX XXXXXXX X XXXX XXXXX XX XXXXXXXXXX.

XXXXXX:
XXXXXX XX XXXXXX’X XXXXXXXX XXX XXX XXXXXXXXX XX XXX XXXXXXXXX XXXXXXXXXX XXXXXXXX: XXXXXXXX XX XXXXXX
XXXXXXXXXX XXXXXXXXX (XX) XXX XXXXXXXX XX XXXXXX XXXXXXXXXXXXX XXXXXXXX XXXXXXXXXX XXXXXXXXX (XXX), XXXXXXX
XXXXXXXX XXXX XXX XXXX XX XXXXXX XX XXX XXXXXX XXX XXXXXX X XXXXXXX’X XXXXXXX XX XXXXXXX XXXXX XXXXXXXXXX; XXXXXXXX XX XXXXXX XXXXX’X XXXXXXX, XXXXXXXXXXXXX XX XXXXXXXXXXXX XX XXX XXXXXXXXXXXXXXXX XXXXX; XXXXXXXX XX XXXXXX XXXXXXX XXXXXX XXXXXXXXX, XXXXXXXXXXXXX XX XXXX XXX, XXXXX XXX XXXXX XXXXXXXXXX XXXXX XX
XXXX; XXXXXXXXX XXXXXXXXX, XXXXXXXXXXXXX XX XXXX XXXXXXXXX XXX XXXXXXXXX XXXX XXXXXXX; XXX, XXXXXXXXXX XXXXXXXXXXX, XX XXXXXXXXXXXX XX XXX XXXXX XXXX XXX XXXXXX XX XXXXXXXX XX XXXXX XXXX XXX XXXXXXXX XXXXXXXXXX.
XXXXX XXXXXXXX XXXXXX (XXX), X XXXXXXX XXXXXXXX XX XXX XXXX, XXXXX X XXXX XX XXX XXXXXXX XXXXXXXX XX XXXX XX XXXXX XXXXXXXXX. XXXXXX XX X XXXXX XXXXX XXXXXXXXXXX XXXXXXXXXX XXXXXXXX XXXX XXXXXX XXX XXXXXXXX XXXXXXX XX XXX, XXXXXXXX XXX XXXXXXXXXXXX XXX XXXX XX XXX XXXXXXXXXXXXX XXXXXXXXXX XXXX XXXXX XXXXXXXX.
XX XXXXX, XX XXXXXXXXX XXXXXXXXXX XXXXXXXXXXXX XXX XXXXXX XXX XXX XXXXXXXXX XX XXXXX’X XXXXXXX XXX XXXXXXXXXX XXXXXXXXXXX. XXX, XX XXXXX XXXX, XXXXXX XXX XXX XXXXX XXXXXXXX XXXXXXXX XX XXXXX XXX XXX XXXXXXXXX XX XXXXXX XXXXXXXXX XXX XXXXXXXXX XXXXXXXXX. XXXXXX XX XXXXXXXXX XXXXXXXX XX XX XXXXXXXXX XXX XXXXXX XXXXXXXXXXXXX XXX,XXX XXXXXXXX XXXXXXXXX. XXXX XXX XXXXXX XXXXXXXXXXX XXXXX XX XXXXXXXXX XXXXX XXX XXXXXX XXXXXXXXXXX, XXXXX XXXXXXXXX XX XX XXXXXXXXXXX XXXXXXXXX XXX XXXX XXXX XXXXXXXX XX XXXXXXX XXXX XXXXXXXXX XXXX XXXXXX.

XXXXXX: XXXXX XXXXXXXXXXXXXX XXXXXX XXXX XXXXXX XXXXXX (XX XXX XXXX), XXXX XX:
XX XXXXXXXXXXX XXX XXX XXXXX XXXXX XXXX-XXX-XXXXX XXXXXXXXXX XXXXXXXX XXXXXX® XXX XXXXXXXXX XX XXXXX XXXXXXX XX XXXXXXXX XX XXXXXXXXXX XXXXXXXXXXX XXX XXXXX’X XXXXXXX XXX XXXXXXXXXX XXXXXXXXXXX XX XXXXXXXXX XXX XXXXXXX XXXX, XXXXXXXXXXXX. XX XXXXXXX XXXX, XXX XXXXXXXX XXXXXXXX XXXXXXXX XX XXXXX XXX XXX XXXXXXXXXX XXXXXXXXXXX XX XXXXXX XXXXXXXXX (XX) XXX XXXXXXXXX XXXXXXXXX (XXX).

XXXXXXX XXXXXXX:

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
X.X. XXXXXX XX XXXXXX XXX XX.X XXXXXXX. XXXXXXXXXXXXX XXXXXXXXXXX XXXXX XXXXXX XXX XXXXXX XXX XX.X XXXXXXX, XXXXX
XXXXXXXX XX XXXXXXXXXXX X.X XXXXXXX XXXXXX XX XXXXXXXX XXXXX.

XXXXXXX XXXXXXXXX XXXXXXXXXXX XXXXXXX:

XXXXXX: XXXXXX XXXX XX-X, XXXX XX:
XXXXX XXX XXXXXX XXX XXXXXXX XXX XXXXXXXXXX XXXXXXXXXXX XX XXXXXX XXXXXXXXX XXXXXXXXXX XXXXXXX XX XXXXX, XXXXXXXXXX XXXXXXXXXXXX XX XXXXX, XXXXXXXXX XXXXX'X XXXXXXX XX XXX X.X. XXX XXX XXXXXXXX XXXXX (XX), XXXXXX XX XXX X.X., XX XXX XXXXX, XXX XXXXXXXXXX XXX XXXXX XXXXXXXXXXXXXXXXX XX XXX X.X. XXX XX. XXXXXX XXXXXXXXXX XXXXXXXXXXXX XXX XXXXXXXXXX XXXXXXX XXXX XXXXXXXXX XX XXXXX XXXX.

XXXXXX: XXXXXX XXXX XXXXXX XXXXXX, XXXX XX:
XXXXXX, XXXXXX’X XXXXXXXX XXX XXX XXXXXXXXX XXXXXXXXXX XXXXXXXX, XX XX XXXXXXXXXXX XXX XXXXXXXXXX XXXXXXXXXXX XXX XXXXX X.X. XXX XXXXXXXX XXXXXXXXXX XXXXXX XXX XXXXXXXXXX XXXXXXX, XX XXXXXXXXXXXX XXXXXXXXX XX XXX XXXXX XXXXXXXXX.

XXXX XX:
XXXXX XXX XXXXXX XXX XXXXXXX XXX XXXXXXXXXX XXXXXXXXXXX XX XXXXXX XXXXXXXXX XXXXXXXXXX XXXXXXX XX XXXXX, XXXXXXXXXX XXXXXXXXXXX XX XXXXX, XXXXXXXXX XXXXX’X XXXXXXX XX XXX X.X. XXX XXX XXXXXXXX XXXXX (XX), XXXXXX XX XXX X.X., XX XXX XXXXX, XXX XXXXXXXXXX XXX XXXXX XXXXXXXXXXXXXXXXX XX XXX X.X. XXX XX. XXXXXX XXXXXXXXXX XXXXXXXXXXXX XXX XXXXXXXXXX XXXXXXX XXXX XXXXXXXXX XX XXXXX XXXX.

XXXXXXXXXXXXXX® XXXXXXX:
XXXXX XXXXXXXX XXXXX XX XXXXXX & XXXXXXXX.
XXXXXXXX XXX XXXXXXXX XX XXXXX.

XXXXXXX XXXXXXX:

XXXXXX: XX XXXX XXXXXXX (XX XXX XXXX):
X.X. XXXXXXXXXXXXXX XXXXX...XXXXXX/XXXXXXXX XXXXXXXXX XXXXXX XXXX XXXXXXX XXX XXXXXXXX XX XXX XXXXXXXXXX XX XXXXX XXXX, XXXX XXXXX XXXX XX XX XXXXXXX, XXXXXXXXX XXX XXXXXXX XXXXXX XX XXXXXXXX. XXXXX XXXXXXXXXXXXX XXX XXX XXXXXX/XXXXXXXX XXXXXXXXX XXXXXXXX XX XXXX XX XXX XXX-XX XXXX-XXXXXX XXXXXX, XXXXXXXXX XXX XXXXXX XXXX XX XXX XXXXXXXXXXX XXXXXX.

XXXXXX: XXXXXX XXXXXXXXXXXX X-X (XX XXX XXXX):
XXXXXX XXXXXXXXXXXX XXX XXX XXXXXX XXXXX, XXXXXXXXXXXX XXXXXXXX X.X., XXXX XXXXXXX XXXX X XXXXXXX XXXXXXXXX XXXX XXXX XXXXXXXXXXXXXXX XXX XXX. XXXXXXXX XXXX XXXXXX XX XXXXXXXXXXXX XXXXXXXX XXX XXXXXX® XXX XX XX XXXXXX XXXX XXXXX XX, XXXX. XXXXX XXXXXXX XXXXXXX XXXXXXXXXXXXX, XXXX XXX XXX XXXXXXX XXXXXX XX XXXX XXXXXXXXXXXX XXXXXXXX XXXXX XXXX X, XXXX.

XXXXXXXXXXXXXX® XXXXXXX:
XXXXX XXXXXXXX XXXXX XX XXXXXX & XXXXXXXX.
XXXXXXXX XXX XXXXXXXX XX XXXXX.

Shaded Cells

A shaded cell signifies potentially incomplete data. E.g. A shaded cell in "Change (+/-)" means there is no corresponding value, i.e. there is data for 2001, but no data for 2000. This could signify a product launch, first time disclosure of sales, a product acquisition or missing data.

A shaded cell containing n/a signifies valid data followed by blank or zero values. E.g. A shaded cell containing n/a in "Change (+/-)" means a value is present for 2000, but blank for 2001. This could signify a product disposal / withdrawal, discontinuation of disclosure or missing data.

XXXXXXXX:
X) +XXXX XXXXXX XXXXX - XX.
X) +XXXX XXXXXXXXXXXXX XXXXXXXXXXXXXXX XXXXX.

XXXXXXXX:
X) +XXXX XXXXXX XXXXX - XX
X) +XXXXX XXXXXXXXXXXXX XXXXXXXXXXXXXXX XXXXX.